Barclays initiated coverage of Incyte (INCY) with an Overweight rating and $90 price target The firm sees “value-inflecting” data readouts for the company in the second half of 2025 and 2026. It believes the pivotal data for tafasitamab in diffuse large B-cell lymphoma and the Phase 2 data for povorcitinib in chronic spontaneous urticaria patients as providing the next legs of growth for Incyte.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Strong Financial Performance and Strategic Initiatives Under New Leadership Drive Buy Rating
- Incyte price target raised to $79 from $73 at Truist
- Incyte price target raised to $60 from $52 at BMO Capital
- Cautious Outlook on Incyte: Sell Rating Amid Long-Term Growth Concerns and Competitive Pressures
- Incyte price target raised to $68 from $62 at UBS